Therapies targeting against TNF-α, IL-1 and IL-6 have demonstrated the favorable clinical outcomes in patients with RA, highlighting the critical role of pro-inflammatory cytokines in RA pathophysiology. Here, IL6 is linked to rheumatoid arthritis.